Copyright
©The Author(s) 2015.
World J Virology. May 12, 2015; 4(2): 56-77
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.56
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.56
Table 1 Antiretroviral drugs class
| Antiretroviral class | Generic name drug | Trade name/manufacturer/approval (yr) |
| Nucleos(t)ide reverse transcriptase inhibitors | Abacavir (ABC) | Ziagen® ViiV Healthcare (1998) |
| Didanozine (ddl) | Videx® Bristol-Myers Squibb Co. (1991) | |
| Emtricitabine (FTC) | Emtriva® Gilead Sci. (2003) | |
| Lamivudine (3TC) | Epivir® GlaxoSmithKline (1995) | |
| Stavudine (d4T) | Zerit® Bristol-Myers Squibb Co. (1994) | |
| Tenofovir (TDF) | Viread® Gilead Sci. (2001) | |
| Zidovudine (AZT) | Retrovir® ViiV Healthcare (1987) | |
| Zalcitabine (ddC) | Hivid® Roche (1992) | |
| Non-nucleoside reverse transcriptase inhibitors | Delavirdine (DLV) | Rescriptor® Pfizer (1997) |
| Efavirenz (EFV) | Sustiva® Bristol-Myers Squibb Co. (1998) | |
| Stocrin® Merck Sharp, Dohme (1998) | ||
| Nevirapine (NVP) | Viramune® Boehringer Ingelheim (1996) | |
| Etravirine (ETR) | Intelence® Janssen-Cilag (2008) | |
| Rilpivirine (RPV) | Edurant® Janssen-Cilag (2011) | |
| Protease inhibitors | Amprenavir | Agenerase® GlaxoSmithKline (1999) |
| Atazanavir | Reyataz® Bristol-Myers Squibb Co. (2003) | |
| Darunavir | Prezista® Janssen-Cilag (2006) | |
| Fosamprenavir | Lexiva® ViiV Healthcare (2003) | |
| Indinavir | Crixivan® Merck and Co. (1996) | |
| Lopinavir | Kaletra® Abbott (2000) | |
| Nelfinavir | Viracept® ViiV Healthcare (1997) | |
| Ritonavir | Norvir® AbbVie Inc. (1996) | |
| Saquinavir | Invirase® Roche (1995) | |
| Tipranavir | Aptivus® Boehringer Ingelheim (2005) | |
| Fusion inhibitors | Enfuvirtide, T-20 | Fuzeon® Hoffmann La Roche (2003) |
| Integrase strand transfer inhibitors | Dolutegravir (DTG) | Tivicay® GlaxoSmithKline (2013) |
| Elvitegravir (EVG) | Stribild® Gilead Sci. (2012) | |
| Raltegravir (RAL) | Isentress® Merck and Co. (2007) | |
| Entry inhibitors (CC chemokine receptor 5 antagonists) | Selzentry | Maraviroc® Pfizer (2007) |
- Citation: Cunha JD, Maselli LMF, Stern ACB, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virology 2015; 4(2): 56-77
- URL: https://www.wjgnet.com/2220-3249/full/v4/i2/56.htm
- DOI: https://dx.doi.org/10.5501/wjv.v4.i2.56